NCT07266350 2025-12-05
A Non-interventional Registration Study of Monotherapy or Combination Regimens Based on Camrelizumab or Famitinib for the Treatment of Cervical Cancer
Chongqing University Cancer Hospital
Not yet recruiting
Clinical Trials
12 trialsNCT05713994 2025-03-25
CCGLC-001
Tongji Hospital
Recruiting
NCT06333561 2025-02-06
HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma
Sun Yat-sen University
Recruiting
NCT06485271 2024-07-03
A Real-world Study of Camrelizumab Alone or in Combination With Apatinib/Chemotherapy for Advanced Gastric Cancer
Changzhi People's Hospital Affiliated to Changzhi Medical College
Recruiting
NCT05717738 2024-06-13
CCGLC-008
Tongji Hospital
Recruiting
NCT06376773 2024-04-19
Neoadjuvant Treatment Based on Gastric Cancer Molecular Subtyping.
Fujian Medical University
Completed
NCT04627012 2024-03-06
Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma
Sun Yat-sen University
Completed
NCT06235164 2024-01-31
The Safety and Efficacy of Neoadjuvant Immunochemotherapy Followed by Laparoscopic Gastrectomy for Gastric Cancer
Fujian Medical University
Unknown
NCT04793139 2021-03-11
Efficacy and Safety of Camrelizumab in Real-World Prospective Study
Guangdong Association of Clinical Trials
Unknown
NCT04771715 2021-02-25
Regorafenib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Patients With Advanced Colorectal Cancer
Peking Union Medical College Hospital
Unknown
NCT04631146 2020-11-17
Efficacy and Safety of Camrelizumab in Real-World Study
Guangdong Association of Clinical Trials
Unknown
NCT04616040 2020-11-04
A Real-world Study Evaluating the Usage of Camrelizumab in Chinese Patients With Advanced Esophageal Cancer
Peking University
Not yet recruiting